Literature DB >> 23379345

Viologen-Phosphorus Dendrimers Inhibit α-Synuclein Fibrillation.

Katarzyna Milowska1, Justyna Grochowina, Nadia Katir, Abdelkrim El Kadib, Jean-Pierre Majoral, Maria Bryszewska, Teresa Gabryelak.   

Abstract

Inhibition of α-synuclein (ASN) fibril formation is a potential therapeutic strategy in Parkinson's disease and other synucleinopathies. The aim of this study was to examine the role of viologen-phosphorus dendrimers in the α-synuclein fibrillation process and to assess the structural changes in α-synuclein under the influence of dendrimers. ASN interactions with phosphonate and pegylated surface-reactive viologen-phosphorus dendrimers were examined by measuring the zeta potential, which allowed determining the number of dendrimer molecules that bind to the ASN molecule. The fibrillation kinetics and the structural changes were examined using ThT fluorescence and CD spectroscopy. Depending on the concentration of the used dendrimer and the nature of the reactive groups located on the surface, ASN fibrillation kinetics can be significantly reduced, and even, in the specific case of phosphonate dendrimers, the fibrillation can be totally inhibited at low concentrations. The presented results indicate that viologen-phosphorus dendrimers are able to inhibit ASN fibril formation and may be used as fibrillar regulating agents in neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23379345     DOI: 10.1021/mp300636h

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

Review 1.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

2.  Exploring the Transition of Human α-Synuclein from Native to the Fibrillar State: Insights into the Pathogenesis of Parkinson's Disease.

Authors:  Naveed Ahmad Fazili; Aabgeena Naeem
Journal:  J Fluoresc       Date:  2016-06-30       Impact factor: 2.217

Review 3.  Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.

Authors:  Mine Silindir Gunay; A Yekta Ozer; Sylvie Chalon
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 4.  Alpha-Synuclein-Nanoparticle Interactions: Understanding, Controlling and Exploiting Conformational Plasticity.

Authors:  Mariapina D'Onofrio; Francesca Munari; Michael Assfalg
Journal:  Molecules       Date:  2020-11-29       Impact factor: 4.411

5.  Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons.

Authors:  Raquel Ferrer-Lorente; Tania Lozano-Cruz; Irene Fernández-Carasa; Katarzyna Miłowska; Francisco Javier de la Mata; Maria Bryszewska; Antonella Consiglio; Paula Ortega; Rafael Gómez; Angel Raya
Journal:  Biomacromolecules       Date:  2021-10-06       Impact factor: 6.988

Review 6.  Dendrimers as Antiamyloid Agents.

Authors:  Svetlana A Sorokina; Zinaida B Shifrina
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

Review 7.  Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics.

Authors:  Serge Mignani; Xiangyang Shi; Maria Bryszewska; Dzmitry Shcharbin; Jean-Pierre Majoral
Journal:  Explor Target Antitumor Ther       Date:  2022-02-25

Review 8.  First-in-Class Phosphorus Dendritic Framework, a Wide Surface Functional Group Palette Bringing Noteworthy Anti-Cancer and Anti-Tuberculosis Activities: What Lessons to Learn?

Authors:  Serge Mignani; Jérôme Bignon; Xiangyang Shi; Jean-Pierre Majoral
Journal:  Molecules       Date:  2021-06-17       Impact factor: 4.411

9.  Viologen-phosphorus dendrimers exhibit minor toxicity against a murine neuroblastoma cell line.

Authors:  Joanna Lazniewska; Katarzyna Milowska; Nadia Katir; Abdelkim El Kadib; Maria Bryszewska; Jean-Pierre Majoral; Teresa Gabryelak
Journal:  Cell Mol Biol Lett       Date:  2013-07-26       Impact factor: 5.787

Review 10.  Cytotoxicity of Dendrimers.

Authors:  Anna Janaszewska; Joanna Lazniewska; Przemysław Trzepiński; Monika Marcinkowska; Barbara Klajnert-Maculewicz
Journal:  Biomolecules       Date:  2019-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.